Please log in to determine if you are eligible to purchase PT Programs.
B-ALL MINIMAL RESIDUAL DISEASE - BALL
BALL
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Analyte Challenges per Shipment Number of Shipments
B-ALL minimal residual disease 3 Two shipments per year

Program BALL is intended for laboratories that currently or will begin to perform minimal residual disease (MRD) testing (rare event analysis) for B lymphoblastic leukemia/lymphoma. The cases presented will be a mixture of Children's Oncology Group (COG) approved B-ALL MRD method and laborotory developed assays.

Program Information

  • Two 1.1-mL specimens containing a cell line/whole blood mixture simulating B lymphoblastic leukemia/lymphoma minimal residual disease
  • One online case consisting of gated dot plots

This program has stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada.

Shipping Schedule

  • Shipment A: January 18
  • Shipment B: July 13






Customers Who Bought This Item Also Bought
Flow Cytometry in Evaluation of Hematopoietic Neoplasms: A Case-Based Approach
VIEW DETAILS >